AtriCure, Inc. (NASDAQ:ATRC) Stock Holdings Trimmed by Royce & Associates LP

Royce & Associates LP lessened its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 62.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,482 shares of the medical device company's stock after selling 40,303 shares during the quarter. Royce & Associates LP owned approximately 0.05% of AtriCure worth $748,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in AtriCure in the fourth quarter valued at $3,716,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of AtriCure by 31.5% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company's stock worth $14,038,000 after acquiring an additional 119,929 shares during the period. Champlain Investment Partners LLC lifted its holdings in shares of AtriCure by 4.3% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company's stock worth $78,253,000 after acquiring an additional 115,813 shares during the period. Two Sigma Advisers LP boosted its position in shares of AtriCure by 14.6% in the third quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company's stock worth $18,621,000 after acquiring an additional 84,700 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in AtriCure in the third quarter valued at approximately $1,991,000. Institutional investors and hedge funds own 99.11% of the company's stock.

Remove Ads

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. This represents a 25.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is owned by insiders.

AtriCure Stock Down 3.5 %

Shares of NASDAQ ATRC traded down $1.23 during trading on Wednesday, reaching $33.62. 1,072,526 shares of the stock were exchanged, compared to its average volume of 658,620. The business's 50-day moving average price is $38.24 and its 200 day moving average price is $33.89. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -35.39 and a beta of 1.53. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ATRC shares. Stifel Nicolaus lifted their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Oppenheimer lifted their target price on AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Canaccord Genuity Group upped their price target on AtriCure from $61.00 to $66.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $51.00 price objective on shares of AtriCure in a research note on Friday, March 21st. Finally, JMP Securities reissued a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.56.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.